Unfractionated and low-molecular-weight heparin for hypercoagulability in dogs and cats

Veterinary Medicine

Volumn 102, Issue 3, 2007, Pages 187-202

  Harnett, Bryan E ^a   Kerl, Marie E ^b  

^a Mission MedVet   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

EID: 34248585427     PISSN: 87507943     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Donahue SM, Otto CM. Thromboelastography: a tool for measuring hypercoagulability, hypocoagulability, and fibrinolysis. J Vet Emerg Crit Care 2005;15:9-16.
2. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698.
3. Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev 1994;8:37-55.
4. Johnson LR, Lappin MR, Baker DC. Pulmonary thromboembolism in 29 dogs: 1985-1995. J Vet Intern Med 1999;13:338-345.
5. Otto CM, Rieser TM, Brooks MB, et al. Evidence of hypercoagulability in dogs with parvoviral enteritis. J Am Vet Med Assoc 2000;217:1500-1504.
6. Palmer KG, King LG, Van Winkle TJ. Clinical manifestations and associated disease syndromes in dogs with cranial vena cava thrombosis: 17 cases (1989-1996). J Am Vet Med Assoc 1998;213:220-224.
7. Liska WD, Poteet BA. Pulmonary embolism associated with canine total hip replacement. Vet Surg 2003;32:178-186.
8. Falconer L, Atwell R. Feline aortic thromboembolism. Aust Vet Pract 2003;33:20-32.
9. Norris CR, Griffey SM, Samii VF. Pulmonary thromboembolism in cats: 29 cases (1987-1997). J Am Vet Med Assoc 1999;215:1650-1654.
10. Schermerhorn T, Pembleton-Corbett JR, Kornreich B. Pulmonary thromboembolism in cats. J Vet Intern Med 2004;18:533-535.
11. Smith SA, Tobias AH, Jacob KA, et al. Arterial thromboembolism in cats: Acute crisis in 127 cases (1992-2001) and long-term management with low-dose aspirin in 24 cases. J Vet Intern Med 2003;17:73-83.
12. Davidson BL, Rozanski EA, Tidwell AS, et al. Pulmonary thromboembolism in a heartworm-positive cat. J Vet Intern Med 2006;20:1037-1041.
13. Allwood AJ, Downend AB, Brooks MB, et al. Anticoagulant effects of low molecular weight heparin in healthy cats (abst). J Vet Emerg Crit Care 2004;14:S1.
14. Mischke R, Grebe S. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin. Res Vet Sci 2000;69:241-247.
15. Nimmerfall K, Mischke R. Effect of unfractionated and low-molecular-weight heparin on platelet aggregation and in vitro bleeding time in dogs [German]. Dtsch Tierarztl Wochenschr 1999;106:439-444.
16. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
17. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114 (5 suppl):489S-510S. [Erratum in: Chest 1999;115:1760.]
18. Hopper K, Bateman S. An updated view of hemostasis: mechanisms of hemostatic dysfunction associated with sepsis. J Vet Emerg Crit Care 2005;15:83-91.
19. Good LI, Manning AM. Thromboembolic disease: physiology of hemostasis and pathophysiology of thrombosis. Compend Contin Educ Pract Vet 2003;25:650-659.
20. Roncales FJ, Sancho JM. Coagulation activators. In: Feldman BF, Zinkl JG, Jain NC, eds. Schalm's veterinary hematology. 5th ed. Philadelphia, Pa: Lippincott, Williams & Wilkins, 2000;532-537.
21. Luchtman-Jones L, Broze GJ Jr. The current status of coagulation. Ann Med 1995;27:47-52.
22. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-1040. [Erratum in: N Engl J Med 2005;353:2827.]
23. Johnstone IB. Coagulation inhibitors. In: Feldman BF, Zinkl JG, Jain NC, eds. Schalm's veterinary hematology. 5th ed. Philadelphia, Pa: Lippincott, Williams, & Wilkins, 2000;538-542.
24. Darien BJ. Acquired coagulopathy V: thrombosis. In: Feldman BF, Zinkl JG, Jain NC, eds. Schalm's veterinary hematology. 5th ed. Philadelphia, Pa: Lippincott, Williams & Wilkins, 2000;574-580.
25. McNicol PL, Liu G, Harley ID, et al. Patterns of coagulopathy during liver transplantation: experience with the first 75 cases using thromboelastography. Anaest Intensive Care 1994;22:659-665.
26. Allwood AJ, Downend AB, Slensky KA, et al. Evaluation of thromboelastography (TEG) in normal cats (abst). J Vet Emerg Crit Care 2004;14:S1.
27. Verstraete M. Heparin and thrombosis: a seventy year long story. Haemostasis 1990;20 (suppl 1):4-11.
28. Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost 1990;16 Suppl:12-18.
29. Breuhl EL, Scott-Moncrief C, Brooks MB. A prospective study of unfractionated heparin therapy to prevent thrombosis in canine immune-mediated hemolytic anemia (abst). J Vet Intern Med 2005;19:399-400.
30. Fryer JS, McMichael MA, Slater MR. Effect of heparin use on survival to discharge of dogs with immune mediated hemolytic anemia (abst). J Vet Intern Med 2005;19:400.
31. Braz-Ruivo L. Thromboembolic disease in cats. In: Mathews KA. Veterinary emergency and critical care manual. Guelph, Ontario: Lifelearn, 2006;194-197.
32. Mischke RH, Schuttert C, Grebe SI. Anticoagulant effects of repeated subcutaneous injections of high doses of unfractionated heparin in healthy dogs. Am J Vet Res 2001;62:1887-1891.
33. Rozanski EA, Hughes D, Scotti M, et al. The effect of heparin and fresh frozen plasma on plasma antithrombin III activity, prothrombin time and activated partial thromboplastin time in critically ill dogs. J Vet Emerg Crit Care 2001;11:15-21.
34. Plumb DC. Plumb's veterinary drug handbook. 5th ed. Ames, Iowa: Blackwell, 2005;929.
35. Diquelou A, Barbaste C, Gabaig AM, et al. Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs. Vet Clin Pathol 2005;34:237-242.
36. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119 (1 suppl):176S-193S.
37. Baker BA, Adelman MD, Smith PA, et al. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med 1997;157:2475-2479.
38. Mischke R, Jacobs C. The monitoring of heparin administration by screening tests in experimental dogs. Res Vet Sci 2001;70:101-108.
39. Mischke R. Heparin in vitro sensitivity of the activated partial thromboplastin time in canine plasma depends on reagent. J Vet Diagn Invest 2003;15:588-591.
40. Raschke R, Hirsh J, Guidry JR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med 2003;138:720-723.
41. Greene CE, Meriwether E. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats. Am J Vet Res 1982;43:1473-1477.
42. Mischke R, Grebe S, Jacobs C, et al. Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs. Am J Vet Res 2001;62:595-598.
43. Allwood AJ, Downend AB, Simpson SA, et al. Pharmacokinetics of dalteparin and enoxaparin in healthy cats (abst). J Vet Emerg Crit Care 2005;15:S1.
44. Morris TA, Marsh JJ, Konopka R, et al. Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism. Thromb Res 2000;100:185-194.
45. Leadley RJ Jr, Kasiewski CJ, Bostwick JS, et al. Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin. Arterioscler Thromb Vasc Biol 1998;18:908-914.
46. Tater KC, Drellich S, Beck K. Management of femoral artery thrombosis in an immature dog. J Vet Emerg Crit Care 2005;15:52-69.
47. Goodman JS, Rozanski EA, Brown DJ, et al. The effects of low-molecular weight heparin on hematologic parameters in normal cats (abst). J Vet Intern Med 1999;13:268.
48. Smith CE, Rozanski EA, Freeman LM, et al. Use of low molecular weight heparin in cats: 57 cases (1999-2003). J Am Vet Med Assoc 2004;225:1237-1241.
49. Grebe S, Jacobs C, Kietzmann M, et al. Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs [German]. Berl Munch Tierarztl Wochenschr 2000;113:103-107.
50. Lunsford K, Mackin A, Langston C, et al. Pharmacokinetics of the biological effects of subcutaneous enoxaparin in dogs (abst). J Vet Intern Med 2005;19:400.
51. Lauer MA, Houghtaling PL, Peterson JG, et al. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2001;104:2772-2777.
52. McMichael M. Primary hemostasis. J Vet Emerg Crit Care 2005;15:1-8.
53. Jang I-K, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation 2005;111:2671-2683.
54. Abrams-Ogg, A, Mathews, KA. Acute immune-mediated hemolytic anemia in dogs. In: Mathews KA. Veterinary emergency and critical care manual. Guelph, Ontario: Lifelearn, 2006;411-415.